TY - JOUR
T1 - Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome
AU - Glintborg, Dorte
AU - Hermann, Anne Pernille
AU - Andersen, Marianne
AU - Hagen, Claus
AU - Beck-Nielsen, Henning
AU - Veldhuis, Johannes D.
AU - Henriksen, Jan Erik
N1 - Funding Information:
Supported by Fonden for Lægevidenskabelig forskning ved Fyns Amt (Odense, Denmark), Jacob Madsen’s and Olga Madsen’s Foundation (Copenhagen, Denmark), Institute of Clinical Research, Odense University Hospital (Odense, Denmark), AP Møller’s Foundation (Copenhagen, Denmark), Hans and Nora Buchard’s Foundation (Copenhagen, Denmark), K. A. Rohde’s Foundation (Odense, Denmark), Aase and Ejnar Danielsen’s Foundation (Lyngby, Denmark), Eva and Carl Adolf Holm’s Foundation (Copenhagen, Denmark), Dagmar Marshall’s Foundation (Copenhagen, Denmark), The Danish Medical Association (Copenhagen, Denmark), A. J. Andersen’s Foundation (Odense, Denmark), the Novo Nordisk Foundation (Gentofte, Denmark), Overlægerådet Odense University Hospital (Odense, Denmark), and the Danish Diabetes Association (Odense, Denmark).
PY - 2006/8
Y1 - 2006/8
N2 - Objective: To thoroughly examine the mechanisms for insulin resistance in polycystic ovary syndrome (PCOS) and to evaluate the effects of pioglitazone treatment on insulin resistance, β-cell function, LH secretion, and glucose metabolism. Design: Randomized, blinded, placebo-controlled study. Setting: Outpatient clinic, at a university hospital in Denmark. Patient(s): Thirty obese women with PCOS and 14 weight-matched healthy females. Intervention(s): Sixteen weeks of blinded treatment with pioglitazone (30 mg/d) or placebo. Main Outcome Measure(s): Fasting blood samples, 24-hour 20-minute integrated blood sampling (LH, insulin, and C-peptide), euglycemic hyperinsulinemic clamps including 3-3H glucose, and indirect calorimetry were performed before and after the intervention period. Result(s): Patients with PCOS had significantly lower insulin sensitivity compared with controls, including significantly decreased insulin-stimulated oxidative and nonoxidative glucose metabolism. Pioglitazone treatment resulted in significantly lower levels of fasting insulin and significantly higher insulin sensitivity, increased insulin-stimulated glucose oxidation, and increased insulin-stimulated inhibition of lipid oxidation. During 24-hour blood sampling, significantly lower area under-the-curve insulin and lower median insulin levels were observed. Secretion profiles of LH and E2 and T levels did not change significantly. Conclusion(s): Insulin resistance in PCOS was characterized by hyperinsulinemia, impaired insulin-stimulated oxidative and nonoxidative glucose metabolism, which was partly reversed by pioglitazone treatment.
AB - Objective: To thoroughly examine the mechanisms for insulin resistance in polycystic ovary syndrome (PCOS) and to evaluate the effects of pioglitazone treatment on insulin resistance, β-cell function, LH secretion, and glucose metabolism. Design: Randomized, blinded, placebo-controlled study. Setting: Outpatient clinic, at a university hospital in Denmark. Patient(s): Thirty obese women with PCOS and 14 weight-matched healthy females. Intervention(s): Sixteen weeks of blinded treatment with pioglitazone (30 mg/d) or placebo. Main Outcome Measure(s): Fasting blood samples, 24-hour 20-minute integrated blood sampling (LH, insulin, and C-peptide), euglycemic hyperinsulinemic clamps including 3-3H glucose, and indirect calorimetry were performed before and after the intervention period. Result(s): Patients with PCOS had significantly lower insulin sensitivity compared with controls, including significantly decreased insulin-stimulated oxidative and nonoxidative glucose metabolism. Pioglitazone treatment resulted in significantly lower levels of fasting insulin and significantly higher insulin sensitivity, increased insulin-stimulated glucose oxidation, and increased insulin-stimulated inhibition of lipid oxidation. During 24-hour blood sampling, significantly lower area under-the-curve insulin and lower median insulin levels were observed. Secretion profiles of LH and E2 and T levels did not change significantly. Conclusion(s): Insulin resistance in PCOS was characterized by hyperinsulinemia, impaired insulin-stimulated oxidative and nonoxidative glucose metabolism, which was partly reversed by pioglitazone treatment.
KW - LH secretion
KW - PCOS
KW - PPAR-γ agonist
KW - glucose metabolism
KW - hyperinsulinemic clamp
KW - indirect calorimetry
KW - insulin resistance
KW - lipid metabolism
KW - pioglitazone
KW - β-cell function
UR - http://www.scopus.com/inward/record.url?scp=33746537783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746537783&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2005.12.067
DO - 10.1016/j.fertnstert.2005.12.067
M3 - Article
C2 - 16782094
AN - SCOPUS:33746537783
SN - 0015-0282
VL - 86
SP - 385
EP - 397
JO - Fertility and sterility
JF - Fertility and sterility
IS - 2
ER -